贝瑞基因(000710) - 2024 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net loss attributable to shareholders of between 170 million and 250 million yuan for the fiscal year 2024, a reduction in loss of 41.48% to 60.21% compared to a loss of 427.2 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 168 million to 248 million yuan, representing a decrease in loss of 40.51% to 59.70% compared to a loss of 416.8 million yuan last year [2]. - Basic earnings per share are expected to be a loss of 0.48 to 0.71 yuan per share, compared to a loss of 1.21 yuan per share in the previous year [2]. Revenue and Profitability Outlook - The company anticipates a slight decline in total operating revenue for the year, while the overall gross profit margin is expected to increase slightly [4]. Strategic Focus and Operational Improvements - The company is focusing on its core business and tightening operational strategies to enhance its competitive edge and improve sustainable operational capabilities [4]. - The company has conducted a comprehensive review and impairment testing of various assets, which has significantly impacted the net profit for the reporting period [4]. Financial Reporting and Audit Status - The financial data provided is preliminary and has not been audited, with the final figures to be disclosed in the 2024 annual report [5].